|
|
|
Kazia Therapeutics Limited (NASDAQ: KZIA) |
|
Kazia Therapeutics Limited
KZIA's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Kazia Therapeutics Limited growth rates, revenue grew
by 248000 % in the fourth quarter of 2024 from the same quarter a year ago.
Ranking at No. 3533
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.18 %
Kazia Therapeutics Limited net loss increased from $-20 millions, to $-27 millions in fourth quarter of 2024,
• More on KZIA's Growth
|
|
Kazia Therapeutics Limited
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 18.29 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 38.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
• More on KZIA's Valuation
|
|
|
|
|
Kazia Therapeutics Limited
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 18.29 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 38.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
• More on KZIA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
